Invokana lawsuits claim that manufacturers failed to warn patients and their doctors of serious risks linked to the drug. Patient injuries include amputations, kidney damage and diabetic ketoacidosis. As of August 2018, more than 1,000 people had sued the drug’s maker, Johnson & Johnson.
*Update: The first Invokana bellwether trial is set for September 2018.
As of August 2018, 1,036 cases were pending as a part of the Invokana multidistrict litigation (MDL).
The U.S. Judicial Panel on Multidistrict Litigation consolidated Invokana cases in December 2016. These lawsuits make up MDL No. 2750 in a New Jersey federal court.
Lawsuits say Invokana users suffered amputations, diabetic ketoacidosis and kidney damage.
People are suing Invokana’s manufacturers, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals. They are seeking compensation for what happened to them.
The lawsuits are still in their early stages and trials have not yet begun.
According to Johnson & Johnson, there are also federal lawsuits over Invokana pending in California and Missouri.
People filed more cases in state courts in Pennsylvania, California and New Jersey.
People in Canada filed a class action lawsuit.
Patients who suffered below-the-knee amputations after taking Invokana may have a case against Johnson & Johnson.
You or a loved one must have been prescribed Invokana to be eligible to file an Invokana lawsuit.
Generally, the patient must have suffered an injury after taking Invokana, but before the injury was added to the drug’s label.
|Type of Injury||Date of Injury|
|Amputation||Before May 16, 2017|
|Kidney injury||Before June 14, 2016|
|Diabetic ketoacidosis||Before Dec. 4, 2015|
|Urosepsis||Before Dec. 4, 2015|
|Pyelonephritis||Before Dec. 4, 2015|
It is important to compile all medical records related to the injury.
An experienced products liability lawyer can help you determine whether you have a personal injury or wrongful death case.
Invokana is one of several brands of SGLT2 inhibitors targeted in Invokana lawsuits. Other brands mentioned alongside Invokana in injury claims include Invokamet and Jardiance.
Invokamet is made with canagliflozin, the same active ingredient as Invokana, and metformin. Jardiance contains empagliflozin. All three drugs are a part of the gliflozin class of SGLT2 inhibitor drugs.
Invokana lawsuits accuse Johnson & Johnson of being negligent in manufacturing the drug. They also say that the company hid the drug’s dangers from the public and the U.S. Food and Drug Administration.
Lawsuits claim that Johnson & Johnson’s marketing misrepresented the drug’s safety. They say the drug is defective and unreasonably dangerous.
Plaintiffs argue that if Johnson & Johnson had been straightforward about Invokana’s risks, patients may have been prescribed several safer alternatives.
The first Invokana bellwether trial is set for September 2018.
Bellwethers are cases parties select to go to trial first in MDLs and other mass torts. These initial trials help both sides of a lawsuit get an idea of how the remaining cases may play out.
The outcome of bellwether trials can influence settlement negotiations.
There have been no global Invokana settlements or jury verdicts to date.
If settlement negotiations or another resolution of the cases fail, then the remaining lawsuits will move forward to trial.
The diabetes medicines are both members of the thiazolidinedione (TZD) class.
At least one class action lawsuit has been filed in Canada over Invokana. A complaint seeking more than $1 billion in damages was filed in Ontario on behalf of everyone in Canada who ingested Invokana.
The lead plaintiff, Rosalba Joudry, says she discovered the dangers of Invokana through a U.S. television commercial. She contacted her doctor. Tests revealed she was experiencing kidney failure.
The FDA approved Invokana in 2013. It was the first drug in the class.
Since then, the federal agency has issued a number of safety communications about SGLT2 inhibitors.
The FDA requires two black box warnings for SGLT2 inhibitors. Black box warnings are the agency’s strongest warnings.
Two large clinical trials showed that people taking canagliflozin were twice as likely to need leg and foot amputations as people given a placebo. After reviewing these studies, the FDA required a black box warning to be included with Invokana, Invokamet and Invokamet XR.
Invokamet must carry a black box warning that it may cause lactic acidosis. This is a potentially fatal condition characterized by a buildup of lactic acid in the body.
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(888) 645-1617